We welcome Philipp Rathert (PhD) to our team. After spending some time in Industry he held a PostDoc position at the IMP – The Research Institute of Molecular Pathology, where he spent three years working on sensitivity and resistance mechanisms to epigenetic drugs targeting leukemia. His recent Nature paper with the title “Transcriptional plasticity promotes primary and acquired resistance to BET inhibition” demonstrates how cancer cells can evade the deadly effects of BRD4 inhibition.